Go Pro
→ The end may be near for these iconic stocks (From Chaikin Analytics) (Ad)tc pixel Free XOMAP Stock Alerts

XOMA (XOMAP) Competitors

XOMA logo
$24.98 0.00 (0.00%)
As of 07/24/2026
Compare

XOMAP vs. AIMDW, ALVOW, ARAV, ACABW, and BFRIW

Should you buy XOMA stock or one of its competitors? MarketBeat compares XOMA with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with XOMA include Ainos (AIMDW), Alvotech (ALVOW), Aravive (ARAV), Atlantic Coastal Acquisition Corp. II (ACABW), and Biofrontera (BFRIW). These companies are all part of the "pharmaceutical products" industry.

How does XOMA compare to Ainos?

XOMA (NASDAQ:XOMAP) and Ainos (NASDAQ:AIMDW) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
XOMA$7.65MN/AN/AN/AN/A
Ainos$18.11KN/AN/AN/AN/A

In the previous week, XOMA and XOMA both had 1 articles in the media. XOMA's average media sentiment score of 1.87 equaled Ainos'average media sentiment score.

Company Overall Sentiment
XOMA Very Positive
Ainos Very Positive

Company Net Margins Return on Equity Return on Assets
XOMAN/A N/A N/A
Ainos N/A N/A N/A

Summary

XOMA beats Ainos on 1 of the 1 factors compared between the two stocks.

How does XOMA compare to Alvotech?

Alvotech (NASDAQ:ALVOW) and XOMA (NASDAQ:XOMAP) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, dividends, earnings, institutional ownership and profitability.

Company Net Margins Return on Equity Return on Assets
AlvotechN/A N/A N/A
XOMA N/A N/A N/A

In the previous week, Alvotech and Alvotech both had 1 articles in the media. XOMA's average media sentiment score of 1.87 beat Alvotech's score of 0.93 indicating that XOMA is being referred to more favorably in the news media.

Company Overall Sentiment
Alvotech Positive
XOMA Very Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alvotech$559.42MN/AN/AN/AN/A
XOMA$7.65MN/AN/AN/AN/A

Summary

Alvotech and XOMA tied by winning 1 of the 2 factors compared between the two stocks.

How does XOMA compare to Aravive?

XOMA (NASDAQ:XOMAP) and Aravive (NASDAQ:ARAV) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk and valuation.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
XOMA$7.65MN/AN/AN/AN/A
AraviveN/AN/AN/A-$0.90N/A

35.8% of Aravive shares are held by institutional investors. 60.4% of Aravive shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, XOMA had 1 more articles in the media than Aravive. MarketBeat recorded 1 mentions for XOMA and 0 mentions for Aravive. XOMA's average media sentiment score of 1.87 beat Aravive's score of 0.00 indicating that XOMA is being referred to more favorably in the media.

Company Overall Sentiment
XOMA Very Positive
Aravive Neutral

Company Net Margins Return on Equity Return on Assets
XOMAN/A N/A N/A
Aravive N/A N/A N/A

Summary

XOMA beats Aravive on 3 of the 5 factors compared between the two stocks.

How does XOMA compare to Atlantic Coastal Acquisition Corp. II?

XOMA (NASDAQ:XOMAP) and Atlantic Coastal Acquisition Corp. II (NASDAQ:ACABW) are both pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, valuation, analyst recommendations, media sentiment, profitability and earnings.

In the previous week, XOMA had 1 more articles in the media than Atlantic Coastal Acquisition Corp. II. MarketBeat recorded 1 mentions for XOMA and 0 mentions for Atlantic Coastal Acquisition Corp. II. XOMA's average media sentiment score of 1.87 beat Atlantic Coastal Acquisition Corp. II's score of 0.00 indicating that XOMA is being referred to more favorably in the media.

Company Overall Sentiment
XOMA Very Positive
Atlantic Coastal Acquisition Corp. II Neutral

Company Net Margins Return on Equity Return on Assets
XOMAN/A N/A N/A
Atlantic Coastal Acquisition Corp. II N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
XOMA$7.65MN/AN/AN/AN/A
Atlantic Coastal Acquisition Corp. IIN/AN/AN/AN/AN/A

Summary

XOMA beats Atlantic Coastal Acquisition Corp. II on 3 of the 3 factors compared between the two stocks.

How does XOMA compare to Biofrontera?

XOMA (NASDAQ:XOMAP) and Biofrontera (NASDAQ:BFRIW) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, valuation, institutional ownership, profitability and risk.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
XOMA$7.65MN/AN/AN/AN/A
Biofrontera$43.20MN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
XOMAN/A N/A N/A
Biofrontera N/A N/A N/A

In the previous week, XOMA and XOMA both had 1 articles in the media. XOMA's average media sentiment score of 1.87 equaled Biofrontera'saverage media sentiment score.

Company Overall Sentiment
XOMA Very Positive
Biofrontera Very Positive

Summary

Biofrontera beats XOMA on 1 of the 1 factors compared between the two stocks.

Get XOMA News Delivered to You Automatically

Sign up to receive the latest news and ratings for XOMAP and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XOMAP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

XOMAP vs. The Competition

Export
MetricXOMABiotechnology IndustryMedical SectorNASDAQ Exchange
Market CapN/A$434.82M$6.87B$12.26B
Dividend Yield9.29%3.90%2.67%9.79%
P/E RatioN/A3.1627.1423.64
Price / SalesN/A6,592.20517.0889.50
Price / CashN/A13.1350.5459.64
Price / BookN/A83.7010.286.07
Net IncomeN/A-$96.07M$3.60B$331.99M
7 Day PerformanceN/A-0.66%-1.27%-0.63%
1 Month Performance-1.93%-1.07%-0.37%-2.00%
1 Year Performance-2.76%56.07%18.30%13.62%

XOMA Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
XOMAP
XOMA
N/A$24.98
flat		N/AN/A$0.00$7.65MN/A10
AIMDW
Ainos
N/A$0.13
+42.8%		N/A-25.9%$0.00$18.11KN/A40
ALVOW
Alvotech
N/A$0.17
flat		N/A-92.3%$0.00$559.42MN/A4
ARAV
Aravive
N/A$0.04
flat		N/AN/A$0.00N/AN/A20
ACABW
Atlantic Coastal Acquisition Corp. II
N/A$0.00
flat		N/AN/A$0.00N/AN/A15

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:XOMAP) was last updated on 7/25/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Three oil giants buried the same discovery for 50 years
In 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the ...
Behind the Markets | Sponsoredtc pixel
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel